Ravinder Shergill, MD
Critical Care Medicine · Vancouver, WANPI 1053341099
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $10,761 of the $16,128 with a category attached, or 66.7%. 23 manufacturers reported payments, led by Johnson & Johnson at 35.7% of the total. Reporting peaked in 2022 at $8,387 and has fallen 90.3% since, to $817 in 2025. Among critical care medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $98.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$6K
- Medical Device Business Services, Inc.$3K
- Intuitive Surgical$2K
- Pulmonx Corporation$1K
- Boston Scientific$971
- AstraZeneca$831
- plus $3K from 17 others
What the payments were for
- Travel & lodging$10,76167%
- Food & beverage$5,33333%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 24 | $5,757 |
| Medical Device Business Services, Inc. | 7 | $2,706 |
| Intuitive Surgical | 11 | $1,811 |
| Pulmonx Corporation | 5 | $1,423 |
| Boston Scientific | 3 | $971 |
| AstraZeneca | 18 | $831 |
| GSK | 34 | $708 |
| Insmed, Inc. | 21 | $483 |
| Inari Medical, Inc. | 4 | $470 |
| Sanofi | 13 | $321 |
| Regeneron Healthcare Solutions, Inc. | 6 | $122 |
| Philips North America LLC | 3 | $88 |
| Verona Pharma, Inc. | 3 | $85 |
| Amgen | 1 | $73 |
| Jazz Pharmaceuticals Inc. | 2 | $49 |
| Viatris Specialty LLC | 2 | $48 |
| Mallinckrodt Hospital Products Inc. | 1 | $39 |
| Actelion Pharmaceuticals US, Inc. | 1 | $37 |
| ERBE USA Inc | 1 | $36 |
| Genentech USA, Inc. | 1 | $20 |
| United Therapeutics Corporation | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$5,502
- MONARCH$1,746
- Da Vinci Surgical System$1,551
- ZEPHYR ENDOBRONCHIAL VALVE$1,298
- GENERAL PULMONARY$792
- FLOWTRIEVER CATHETER, S$361
- CT THROMBECTOMY SYSTEM KIT$361
- BREZTRI$250
- ULTRAFLEX$133
- DUPIXENT$128
- AIRSUPRA$125
- NUCALA$122
How this compares
$16,128 in reported general payments places this provider in the 95th percentile of 115 critical care medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 139 | $218,494 |
| Ambrisentan | 35 | $205,078 |
| Spiriva RespimatTiotropium Bromide | 80 | $95,752 |
| FasenraBenralizumab | 13 | $75,975 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $55,178 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 37 | $33,942 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $28,137 |
| Bosentan | 12 | $14,934 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $14,766 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $9,966 |
| Montelukast Sodium | 328 | $6,166 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $6,008 |
| Mycophenolate Mofetil | 39 | $5,741 |
| Tadalafil | 13 | $5,503 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $5,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $708 | $273,672194 claims |
| AstraZenecaFasenra, Breztri Aerosphere, Symbicort | $831 | $118,87866 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $37 | $14,93412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 115 critical care medicine providers in Washington.
Other critical care medicine in Vancouver
- Bashar AlkinjVancouver$4K
- David SteigerVancouver$1K
- Sarah TuthillVancouver$314
- Vinay GuptaSeattle$185K
- Sara NikravanSeattle$106K
- Michael SouterSeattle$20K
- Oliver McElvaneySeattle$7K
- Sharukh LokhandwalaSeattle$7K
- Kurt JensenTacoma$6K
- Raquel BartzSeattle$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.